How Leptin Counterbalances Insulin to Regulate Body Weight: A New Integrated Model

The paper proposes a five-component model of body weight regulation centered on the counterregulation of insulin by leptin. Key components include: (1) the autonomic nervous system and suprachiasmatic clock coordinating energy intake and expenditure within a circadian framework; (2) interaction with brain reward circuits involving dopamine, ghrelin, melanin-concentrating hormone, and orexin-hypocretin peptides driving feeding and locomotion; (3) leptin counteracting insulin through multiple mechanisms — potentiating CCK-mediated satiation, inhibiting insulin secretion, opposing insulin's lipogenic effects with lipolytic action, and modulating insulin sensitivity; and (4) leptin's role in inhibiting bone mineral accrual, suggesting it helps maintain stability of skeletal, lean, and adipose tissue masses.

This is a narrative review and theoretical synthesis. The author re-examined existing research on autonomic regulation, circadian biology, reward circuits, and peptide hormone signaling to formulate a new integrated model of body weight control. No new experimental data were generated.

Understanding how peptide hormones like leptin, ghrelin, and insulin interact to regulate body weight is fundamental to developing better obesity and metabolic treatments. This model provides a framework for understanding why weight loss triggers hormonal changes that promote weight regain (reduced leptin increases insulin sensitivity and anabolic drive), and why obesity creates a different hormonal landscape (elevated leptin suppresses insulin's fat-storage effects).

This model connects several areas of metabolic research — circadian biology, autonomic regulation, reward neuroscience, and peptide endocrinology — into a single framework. It helps explain persistent clinical puzzles like why weight-loss maintenance is so difficult (leptin drops, insulin sensitivity rises, anabolic drive increases) and why obesity medications targeting single pathways often fail. Modern multi-receptor agonists like tirzepatide, which act on multiple peptide pathways simultaneously, align with this model's emphasis on interconnected regulatory systems.

As a narrative review proposing a theoretical model, this paper does not present new experimental data or systematic evidence synthesis. The model is the author's integration of diverse research areas and has not been directly tested as a unified framework. Some proposed interactions may be oversimplified given the complexity of metabolic regulation.